Immunogenicity, safety and tolerability of 15-valent pneumococcal conjugate vaccine (V114) compared to 13-valent pneumococcal conjugate vaccine (PCV-13) in healthy infants: A systematic review and meta-analysis
Authors:
- Muhammad Zain Ul HaqMHMuhammad Zain Ul Haq
- Hamza IrfanHIHamza Irfan
- Muhammad Shahmeer Ullah ShahMSMuhammad Shahmeer Ullah Shah
- Anusha SumbalASAnusha Sumbal
- Sanila MughalSMSanila Mughal
- Saad AshrafSASaad Ashraf
- Areeba Aamir Ali BasariaABAreeba Aamir Ali Basaria
- AbdullahABAbdullah
- Muhammad Aaqib ChachoMCMuhammad Aaqib Chacho
- Biruk Demisse AyalewBABiruk Demisse Ayalew
Open Access
- 21 May 2025
- journal article
- review article
- Published by Elsevier in Vaccine: X
- Vol. 24
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Serotype distribution, antibiotic resistance, multilocus sequence typing, and virulence factors of invasive and non-invasive Streptococcus pneumoniae in Northeast China from 2000 to 2021Medical Microbiology and Immunology, 2024
- COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individualsVaccine, 2024
- Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A phase III study (V114-033)Vaccine, 2023
- A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)Vaccine, 2023
- Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2)Vaccine, 2023
- A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)Vaccine, 2023
- A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)Vaccine, 2022
- Emergence of a multidrug-resistant and virulent Streptococcus pneumoniae lineage mediates serotype replacement after PCV13: an international whole-genome sequencing studyThe Lancet Microbe, 2022
- A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN)Vaccine, 2022
- Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infantsVaccine, 2018